Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

Evrima Chicago LOS ANGELES, CA / ACCESS Newswire / July 12, 2025 / In an online era shaped by algorithms, avatars, and attention spans shorter than a GIF loop, your digital presence isn’t just a ...

DelveInsight's, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline ...

The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035, registering a compound annual growth rate (CAGR) of 7.4% over the ...

Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna on June 30. The company’s shares closed yesterday at $28.69. Foroohar covers the Healthcare sector, focusing on stocks such ...

Coinbase tends to perform well during periods of high crypto trading activity, but its earnings are highly sensitive to market volatility and regulatory shifts, making consistent profitability a ...

Economic modeling is “very difficult” right now because “things are changing constantly,” Atlanta Fed President Raphael ...

During his Senate confirmation hearings, Health Secretary Robert F. Kennedy Jr. suggested he wouldn’t undermine vaccines. He ...

Moderna has pulled the filing for FDA approval of its flu/COVID combination vaccine. The biotech plans to resubmit later this year with the phase 3 flu vaccine efficacy data the agency wants to see.